Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy

Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy

We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of microbiology, immunology and infection immunology and infection, 2021-04, Vol.54 (2), p.327-330
Hauptverfasser: Beauvais, David, Karleskind, Oriane, Loridant, Severine, Nyga, Remy, Lamiaux, Marie, Moreau, Anne-Sophie, Morschhauser, Franck, Mitra, Suman, Yakoub-Agha, Ibrahim, Sendid, Boualem
Format: Artikel
Sprache:eng
Schlagworte:
CAR T-cell
Il-6
Life Sciences
tocilizumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.
ISSN:1684-1182
1995-9133
1995-9133
DOI:10.1016/j.jmii.2021.02.006